Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.

Article  PubMed  Google Scholar 

Wan EYF, Fung WT, Schooling CM, Au Yeung SL, Kwok MK, Yu EYT, et al. Blood pressure and risk of cardiovascular disease in UK biobank: a Mendelian randomization study. Hypertension. 2021;77(2):367–75.

Article  CAS  PubMed  Google Scholar 

Sander GE, Giles TD. Hypertension and lipids: lipid factors in the hypertension syndrome. Curr Hypertens Rep. 2002;4(6):458–63.

Article  PubMed  Google Scholar 

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.

Article  PubMed  Google Scholar 

Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6): e008552.

Article  PubMed  Google Scholar 

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435–43.

Article  PubMed  Google Scholar 

Koh KK, Quon MJ, Han SH, Lee Y, Park JB, Kim SJ, et al. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011;146(3):319–25.

Article  PubMed  Google Scholar 

Watanabe H, Kosuge K, Nishio S, Yamada H, Uchida S, Satoh H, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 2004;76(3):281–92.

Article  CAS  PubMed  Google Scholar 

Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27(24):2982–8.

Article  CAS  PubMed  Google Scholar 

Sundström J, Gulliksson G, Wirén M. Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis. BMJ Evid Based Med. 2018;23(2):64–9.

Article  PubMed  PubMed Central  Google Scholar 

Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102(15):1748–54.

Article  CAS  PubMed  Google Scholar 

Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374(21):2032–43.

Article  CAS  PubMed  Google Scholar 

Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA. 2019;322(14):1381–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van de Poll SW, Delsing DJ, Wouter Jukema J, Princen HM, Havekes LM, Puppels GJ, et al. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol. 2003;35(1):109–18.

Article  PubMed  Google Scholar 

Cesari M, Pessina AC. Combined antihypertensive and lipid-lowering treatment. Curr Hypertens Rep. 2004;6(4):300–6.

Article  PubMed  Google Scholar 

Rouette J, McDonald EG, Schuster T, Brophy JM, Azoulay L. Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. BMJ Open. 2022;12(6).

Article  PubMed  PubMed Central  Google Scholar 

Machida T, Obara T, Miyazaki M, Inoue J, Mano N. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Ann Hepatol. 2022;27(4): 100699.

Article  CAS  PubMed  Google Scholar 

Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE. Lipid-lowering drug prescriptions in a group of Colombian patients. Biomedica. 2019;39(4):759–68.

Article  PubMed  PubMed Central  Google Scholar 

Rees JMB, Foley CN, Burgess S. Factorial Mendelian randomization: using genetic variants to assess interactions. Int J Epidemiol. 2020;49(4):1147–58.

Article  PubMed  Google Scholar 

Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian cancer. JAMA. 2020;323(7):646–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, et al. Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects. Circulation. 2019;140(4):270–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50(10):1412–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao JV, Liu F, Schooling CM, Li J, Gu D, Lu X. Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study. Diabetologia. 2022;65(4):695–704.

Article  PubMed  Google Scholar 

UK Biobank. Biomarker assay quality procedures: approaches used to minimise systematic and random errors (and the wider epidemiological implications). 2019. https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/biomarker_issues.pdf. Accessed 20 March 2023.

Seyed Khoei N, Wagner KH, Sedlmeier AM, Gunter MJ, Murphy N, Freisling H. Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank. Cardiovasc Diabetol. 2022;21(1):54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu X, Peloso GM, Liu DJ, Wu Y, Zhang H, Zhou W, et al. Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants that contribute to lipid levels and coronary artery disease. Nat Genet. 2017;49(12):1722–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study. Int J Epidemiol. 2020;49(4):1132–40.

Article  PubMed  Google Scholar 

Wang Z, Lu J, Hu J. Association between antihypertensive drugs and hepatocellular carcinoma: a trans-ancestry and drug-target Mendelian randomization study. Liver Int. 2023;43(6):1320–31.

Article  CAS  PubMed  Google Scholar 

Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021;10: e73873.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Clarke R, Bennett D, Guo Y, Walters RG, Hill M, et al. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nat Med. 2019;25(4):569–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, Collins R. METASTROKE Collaboration of the ISGC. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. Eur Heart J. 2018;39(5):354–9.

Article  CAS  PubMed  Google Scholar 

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–97.

Article  CAS  PubMed